Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-19. Cancelled

20. (Previously Presented) A compound represented by the following general formula (1) or a pharmacologically acceptable salt thereof:



wherein

n_1, n_2, and n_3 represent an integer of 1;

R_1, R_2, R_3, R_4, R_5, and R_6 each independently represent a hydrogen atom;

A_1 and A_2 each independently represent a hydrogen atom, a substitutable monocyclic or polycyclic heteroaromatic ring, a partly saturated substitutable polycyclic heteroaromatic ring, a substitutable monocyclic or polycyclic aromatic ring, a partially saturated substitutable polycyclic aromatic ring, a substitutable heteroring, or a group represented by the following formula (2):



.....(2)

wherein

R_7, R_8, R_9, and R_{10} each independently represent a hydrogen atom, a substitutable alkyl group having 1 to 15 carbon atoms, a substitutable alkenyl group having 2 to 15 carbon atoms, a substitutable alkynyl group having 2 to 15 carbon atoms, or a substitutable cyclic alkyl group having 3 to 15 carbon atoms;

W represents a phenyl group;

X represents CH_2;

D represents a group represented by the following formula (6):



.....(6)

wherein

Q represents NR_{12}, wherein R_{12} represents $-(CH_2)_mCOOR_{36}$, wherein m represents an integer of 1 or 2 and R_{36} represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms;

Y represents $-(CH_2)_{m3}-$ wherein m3 represents an integer of 0 to 6; and

B represents $NR_{25}R_{26}$ wherein R_{25} and R_{26} each independently represent a

hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a cyclic alkyl group having 3 to 6 carbon atoms.

21. (Previously Presented) A compound and a pharmacologically acceptable salt thereof according to claim 20, wherein A_1 is an imidazole group and A_2 is an imidazole group or an imidazole group substituted with an alkyl group.

22. (Previously Presented) A compound and a pharmacologically acceptable salt thereof according to claim 20, wherein R_{36} represents a hydrogen atom or an ethyl group.

23. (Previously Presented) A compound or a pharmacologically acceptable salt thereof according to claim 20, wherein R_{25} and R_{26} represent an alkyl group having 1 to 6 carbon atoms.

24. (Previously Presented) A compound or a pharmacologically acceptable salt thereof according to claim 20, wherein the compound is selected from the group consisting of:

3-[(4-dipropylamino-butyl)-(4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-amino]-propionic acid,

[(4-dipropylamino-butyl)-(4-[[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl]-benzyl)-amino]-acetic acid, and

[[4-(dipropyl-amino)-butyl]-(4-[[1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl]-benzyl)-amino]-acetic acid ethyl ester.

25. (Previously Presented) A medical composition, comprising as an active ingredient the compound, or the pharmacologically acceptable salt thereof, according to claim 20.

26. (Previously Presented) A CXCR4 antagonist, comprising as an active ingredient the compound, or the pharmacologically acceptable salt thereof according to claim 20.

27. (Previously Presented) An antiviral drug, comprising as an active ingredient the compound, or the pharmacologically acceptable salt thereof according to claim 20.

28 - 31. Cancelled

32. (Previously Presented) A compound or a pharmacologically acceptable salt thereof according to claim 24, wherein the compound is 3-[(4-dipropylamino-butyl)-(4-

{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-amino]-propionic acid.

33. (Previously Presented) A compound or a pharmacologically acceptable salt thereof according to claim 24, wherein the compound is [(4-dipropylamino-butyl)-(4-[[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl]-benzyl)-amino]-acetic acid.

34. (Previously Presented) A compound or a pharmacologically acceptable salt thereof according to claim 24, wherein the compound is [[4-(dipropyl-amino)-butyl]-(4-[[1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl]-benzyl)-amino]-acetic acid ethyl ester.